Sherbrooke Park Advisers LLC Buys 737 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Sherbrooke Park Advisers LLC lifted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 2.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,038 shares of the biotechnology company’s stock after purchasing an additional 737 shares during the quarter. Sherbrooke Park Advisers LLC’s holdings in Exelixis were worth $1,067,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Coppell Advisory Solutions LLC bought a new stake in Exelixis during the 4th quarter worth approximately $25,000. Colonial Trust Co SC grew its holdings in Exelixis by 616.9% during the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 765 shares during the last quarter. Principal Securities Inc. grew its holdings in Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 373 shares during the last quarter. USA Financial Formulas bought a new stake in Exelixis during the 4th quarter worth approximately $32,000. Finally, Kestra Investment Management LLC bought a new stake in Exelixis during the 4th quarter worth approximately $39,000. 85.27% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, EVP Dana Aftab sold 1,508 shares of the business’s stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $39.00, for a total transaction of $58,812.00. Following the completion of the transaction, the executive vice president now directly owns 693,181 shares in the company, valued at $27,034,059. The trade was a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Christopher J. Senner sold 29,314 shares of the business’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $36.14, for a total value of $1,059,407.96. Following the transaction, the chief financial officer now owns 779,607 shares of the company’s stock, valued at approximately $28,174,996.98. The trade was a 3.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 129,641 shares of company stock worth $4,810,161 over the last ninety days. 2.82% of the stock is owned by corporate insiders.

Exelixis Stock Performance

Shares of NASDAQ EXEL opened at $46.26 on Friday. The stock has a market cap of $12.75 billion, a PE ratio of 26.14, a price-to-earnings-growth ratio of 1.13 and a beta of 0.25. Exelixis, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $48.85. The stock has a fifty day moving average of $37.06 and a 200-day moving average of $35.68.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, sell-side analysts predict that Exelixis, Inc. will post 2.04 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on EXEL shares. Barclays boosted their price target on shares of Exelixis from $25.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. JMP Securities reiterated a “market outperform” rating and set a $41.00 target price on shares of Exelixis in a research report on Thursday, April 17th. Stifel Nicolaus boosted their target price on shares of Exelixis from $36.00 to $38.00 and gave the company a “hold” rating in a research report on Wednesday. UBS Group reiterated an “underperform” rating on shares of Exelixis in a research report on Thursday, April 17th. Finally, Guggenheim restated a “buy” rating and set a $42.00 price target on shares of Exelixis in a research note on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $38.76.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.